Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Cannabidiol  COVID-19 treatment studies for Cannabidiol  C19 studies: Cannabidiol  Cannabidiol   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 56% Improvement Relative Risk Ventilation 25% Hospitalization time -6% Mannumbeth Renjithlal et al. Cannabidiol Prophylaxis Is prophylaxis with cannabidiol beneficial for COVID-19? PSM retrospective 39,285 patients in the USA (Jan - Dec 2020) Lower mortality (p<0.0001) and ventilation (p<0.0001) Mannumbeth Renjithlal et al., SSRN Electronic J., doi:10.2139/ssrn.4336513 Favors cannabidiol Favors control
Cannabis Use and COVID-19 Hospitalization Outcomes. A Retrospective Study
Mannumbeth Renjithlal et al., SSRN Electronic Journal, doi:10.2139/ssrn.4336513 (Preprint)
Mannumbeth Renjithlal et al., Cannabis Use and COVID-19 Hospitalization Outcomes. A Retrospective Study, SSRN Electronic Journal, doi:10.2139/ssrn.4336513 (Preprint)
Jan 2023   Source   PDF  
  All Studies   Meta
Retrospective 1,657,800 COVID-19 hospitalizations in the USA including 13,095 patients with cannabis use disorder, showing lower risk of mortality with cannabis use disorder. The text and Table S2 have conflicting results for mortality: 0.45 [0.36-0.57] versus 0.43 [0.34-0.55].
risk of death, 55.6% lower, RR 0.44, p < 0.001, treatment 380 of 13,095 (2.9%), control 1,430 of 26,190 (5.5%), NNT 39, odds ratio converted to relative risk.
risk of mechanical ventilation, 24.6% lower, RR 0.75, p < 0.001, treatment 925 of 13,095 (7.1%), control 2,455 of 26,190 (9.4%), NNT 43.
hospitalization time, 5.9% higher, relative time 1.06, p < 0.001, treatment mean 7.2 (±12.78) n=13,095, control mean 6.8 (±10.42) n=26,190.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Mannumbeth Renjithlal et al., 28 Jan 2023, retrospective, propensity score matching, USA, preprint, 7 authors, study period 1 January, 2020 - 31 December, 2020.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperCannabidiolAll
Abstract: d pe er re vie we Cannabis use and COVID-19 hospitalization outcomes. A retrospective study. Pr ep rin tn ot Running title: Cannabis use and COVID outcomes This preprint research paper has not been peer reviewed. Electronic copy available at: pe er re vie we Sarath Lal Mannumbeth Renjithlal1, Mohamed Magdi1, Abdullah Zoheb d Authors: Azhar1,Keerthi Renjith1, Richard Alweis1, Nayef El-Daher1, Moghniuddin Mohammed1. Affiliations 1Department of medicine, Rochester regional health/Unity hospital 2Department of Cardiology, Maimonides Medical Center, New York. Disclosure All authors have no conflict of interest Corresponding author: ot All authors received no financial support for the research, authorship, or publication tn Name: Sarath Lal Mannumbeth Renjithlal rin Email: Sarath Lal Mannumbeth Renjithlal: Conceptualization, Methodology, Writing- ep Original draft preparation. Mohamed Magdi.:Writing and reviewing. Abdullah Zoheb Azhar: Writing and Reviewing. Keerthi Renjith: Writing . Richard Alweis: Supervision.: , Nayef El-Daher: Supervision, Reviewing, Moghniuddin Pr Mohammed : Writing, Supervision, Reviewing and Software. This preprint research paper has not been peer reviewed. Electronic copy available at: d pe er re vie we Abstract Background In vitro studies have shown cannabinoids blocking SARS-CoV-2 cellular entry and affecting replication. There is a paucity of data assessing the effect of cannabis on patients hospitalized with COVID in the USA. The aim of our study was to assess mortality and complication rates in patients hospitalized with COVID stratified by cannabis use. Methods We used the National Inpatient Sample, the largest all-payer inpatient database with 95% of US hospitalizations from 49 states, to identify all COVID hospitalizations from January 01, 2020, to December 31, 2020. We included all adult patients without missing mortality and gender information. The whole cohort was stratified by cannabis use into two groups (cannabis use disorder (CUD) vs. no CUD). We performed propensity score matching based on multiple patient and hospital characteristics to assess the outcome difference. Results ot A total of 1,657,800 hospitalizations were included. Of these, 13,095 (0.79%) were cannabis users and were likely to be male (65.6%) and Black (35%) compared to non-cannabis users. tn After propensity score matching, the CUD group had lower mortality (2.9% compared to 5.5%, OR 0.43 [CI 0.34 – 0.55] p <0.001). They also had lower rates of non-invasive (2.9% vs. 3.9 p <0.014), invasive mechanical ventilation (9.4% vs. 7.1%, p<0.001) and ECMO use rin (0.1 vs. 0.3 p <0.014). They also had a lower rate of septic shock (3.1% vs. 4% p<0.03) and lesser GI bleeding (3.3% vs. 2.3% p<0.005) compared to no CUD. The cost of hospitalization in the CUD group was significantly lower. There was no significant difference between the ep other complications assessed. Pr Conclusion We found lower mortality rates, lesser need for mechanical ventilation, and reduced hospitalization expenses among cannabis users hospitalized with COVID-19. Further This preprint research paper has not been peer reviewed. Electronic copy available at: research is required to determine whether cannabinoid is a candidate for the treatment and pe er re vie we d prevention of..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop